𝔖 Bobbio Scriptorium

✦ LIBER ✦

59 GM-CSF does not reduce the incidence of febrile neutropenia during combination chemotherapy for small cell lung cancer (SCLC). A west of Scotland lung cancer group trial

✍ Scribed by Milroy, R.; Dorward, A.; Bicknell, S.; Vernon, D.; Cameron, C.; McGregor, K.; Steward, W.

Book ID: 123312670
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 152 KB
Volume: 18
Category: Article
ISSN: 0169-5002
DOI: 10.1016/S0169-5002(97)89338-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-848 Prevention of chemotherapy-induced

P-848 Prevention of chemotherapy-induced febrile neutropenia (FN) by the addition of granulocyte-colony stimulating factor (G-CSF) to antibiotics in small cell lung cancer (SCLC) patients at risk of FN: A prospective economic evaluation along a Dutch randomised phase III trial

✍ Timmer-Bonte, J.; Adang, E.; de Boo, T.; Tjan-Heijnen, V. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 289 KB

A multicentre, randomised, double-blind,

A multicentre, randomised, double-blind, placebo controlled, parallel group study to investigate the efficacy and tolerability of leucomax® (molgramostim; rHu GM-CSF) in conjunction with combination chemotherapy in the treatment of intermediate / poor prognosis patients with small cell lung cancer (SCLC)

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 143 KB